MINISTER OF NATURAL RESOURCES, GOVERNMENT OF NEW BRUNSWICK
"By targeting committed investors and maintaining strong regulatory and Indigenous relations, the province hopes to accelerate responsible mineral development and establish itself as a serious, results-oriented jurisdiction."
"Since exploration depends on financing, our efforts focus on supporting associations and regulators to facilitate funding and advance mining projects in Québec."
"In 2025, Brunswick will advance our flagship Mirage project in Québec with a resource estimate, expand exploration in Greenland following its first-ever lithium discovery, and drill our other assets like Anatacau."
"Newfoundland and Labrador is strongly committed to developing critical minerals. Green Bay is set to be one of few copper mines in the province, making it key to that strategy."
"The human connection between pilots, crews, and clients – along with the need for in-the-moment decision-making – ensures that manned operations remain essential."
VICE-PRESIDENT & MARKET LEAD - MINERALS & METALS NORTH AMERICA, ATKINSRÉALIS
"To maximize its potential, it will be crucial to break down silos between mining companies, communities, and government in any accelerated delivery framework."
"If Québec could issue permits faster than other jurisdictions, it would create a competitive advantage. With the US also moving to streamline permitting, it is turning into a race to attract more capital."
"At AEMQ, our primary focus is advocating for regulatory reforms to simplify the legislation, eliminate redundancies, and accelerate administrative and approval processes."
"It is clear that some parts of Canada have been developing their natural resources, while others have not. Nova Scotia has been among the latter. It is time for us to step up, and I am trying to lead Nova Scotia in that direction."
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.